Test Price
2,800 AED✅ Home Collection Available
SUFU Gene Sequencing for Familial Desmoplastic Medulloblastoma (NGS) in UAE – 2,800 AED – DNA Labs UAE
Executive Summary & Core Metrics
Executive Summary
This advanced next-generation sequencing (NGS) assay provides comprehensive analysis of the SUFU gene coding region to detect germline pathogenic variants associated with familial desmoplastic medulloblastoma. Early identification enables proactive surveillance, genetic counselling, and improved clinical outcomes for at-risk individuals and their families. DNA Labs UAE delivers this test under DHA Facility License 1143 with ISO 9001:2015 accreditation.
Test Overview & Methodology
The SUFU gene sequencing test employs Illumina-based NGS technology to interrogate all coding exons and flanking intronic regions of the SUFU gene. Pathogenic variants in SUFU are established drivers of the desmoplastic subtype of medulloblastoma and are implicated in hereditary cancer predisposition syndromes. This test is recommended for individuals with a personal or family history of medulloblastoma, particularly the desmoplastic variant, and for asymptomatic relatives who carry a known familial mutation. Results are correlated with clinical, radiological, and histopathological findings to guide multidisciplinary management.
| Parameter | DNA Labs UAE – SUFU NGS Test | Conventional Alternative (Sanger Sequencing) |
|---|---|---|
| Detection Sensitivity | 99.9% – full gene coding region coverage | Limited to selected exons; misses deep intronic splice variants |
| Methodology | NGS on Illumina platform with LC-MS/MS validation | Capillary electrophoresis (Sanger) |
| Turnaround Time | 3–4 Weeks | 5–6 Weeks |
| Cost | 2,800 AED | Approximately 3,500 AED |
Physician Insight & Safety Protocols
“SUFU germline testing provides critical risk stratification for families affected by desmoplastic medulloblastoma. However, a pathogenic variant must always be interpreted within the context of complete pedigree analysis, brain MRI surveillance history, and histopathological confirmation. This test is a powerful screening tool but never a standalone diagnostic endpoint. I strongly recommend that all results be reviewed during a dedicated genetic counselling session before any clinical decisions are made.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory – Result Interpretation & Medication Guidance
Do not discontinue, initiate, or modify any prescribed therapy or surveillance schedule solely on the basis of a genetic test result. All findings must be discussed with the referring specialist and a certified genetic counsellor. Genetic testing is an adjunct to, not a substitute for, clinical judgment and imaging surveillance.
Exclusion Criteria & Safety Red Flags
- Individuals under 18 years require written parental or legal guardian consent and pre-test genetic counselling consistent with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Insufficient sample volume (minimum 2 mL whole blood in EDTA, 3 µg DNA, or a fully saturated FTA card) may necessitate re-collection.
- Acute febrile illness, active systemic infection, or recent blood transfusion (within 7 days) can compromise sample quality. Contact the laboratory before booking.
- Emergency Red Flags: If after receiving the genetic report you experience new-onset severe headache, persistent vomiting, balance disturbance, visual changes, or focal neurological signs, seek immediate emergency medical attention and inform the emergency physician of the SUFU genetic result.
Patient FAQ & Clinical Guidance
1. What is the SUFU gene NGS test and who should consider it?
A: This test analyzes the entire coding region of the SUFU gene using next-generation sequencing to identify germline mutations linked to familial desmoplastic medulloblastoma. It is recommended for individuals with a personal or first-degree family history of medulloblastoma, especially the desmoplastic subtype, and for asymptomatic siblings of an affected child to guide early surveillance brain MRI protocols.
2. How is the sample collected, and is home collection available?
A: A qualified phlebotomist collects a venous whole blood sample in an EDTA tube, or an FTA card with a single dried blood drop may be accepted. Previously extracted genomic DNA can also be submitted. DNA Labs UAE offers VIP Mobile Phlebotomy with temperature-controlled cold-chain transport daily from 8 AM to 11 PM across all UAE emirates. All collection procedures comply with DHA and MOHAP infection control standards.
3. What should I do if the SUFU result is positive?
A: A positive result for a pathogenic SUFU variant indicates hereditary predisposition to desmoplastic medulloblastoma and also to basal cell carcinoma. You will receive a telephonic consultation with our Consultant Medical Genetics specialist to discuss the implications. Recommended next steps include formal genetic counselling, regular brain MRI surveillance, dermatological monitoring, and family cascade testing. Your report will be shared with your referring physician, and a multidisciplinary team meeting can be arranged. All genetic data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
4. How long does the test take and when will I receive the report?
A: The standard turnaround time is 3–4 weeks from the date the sample reaches our laboratory. This allows for library preparation, NGS sequencing, bioinformatics analysis, variant confirmation, and clinical interpretation. Reports are delivered electronically via a secure link and are also sent to your referring healthcare provider.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in full compliance with UAE federal data protection and healthcare information governance frameworks. All genetic data generated from the SUFU gene sequencing test is processed, stored, and transmitted in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent, data minimization, purpose limitation, and the right to access and erasure are strictly enforced. No genetic information is shared with third parties without explicit written authorization. The laboratory is ISO 9001:2015 accredited (Cert: INT/EGQ/2509DA/3139) and holds a valid DHA Facility License (No. 1143). Clinical safety and patient consent protocols follow the provisions of Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | SUFU Gene Sequencing for Familial Desmoplastic Medulloblastoma (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA tube), Extracted Genomic DNA (≥3 µg), or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina Platform with LC-MS/MS Validation |
| ICD-10-CM Code | Z15.09 (Genetic susceptibility to other malignant neoplasm), C71.6 (Cerebellar medulloblastoma – applicable for affected patients) |
| LOINC Code | 55233-1 (SUFU gene targeted mutation analysis) |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians